Compare TURB & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TURB | GTBP |
|---|---|---|
| Founded | 2013 | 1965 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5M | 17.7M |
| IPO Year | 2023 | 2016 |
| Metric | TURB | GTBP |
|---|---|---|
| Price | $1.48 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 144.9K | ★ 942.5K |
| Earning Date | 04-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.26 |
| 52 Week High | $20.44 | $2.21 |
| Indicator | TURB | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 37.09 |
| Support Level | $1.42 | $0.26 |
| Resistance Level | $1.78 | $0.44 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 23.18 | 5.26 |
Turbo Energy SA is an integrator of AI-driven energy storage and intelligent energy management solutions focused on transforming how energy is generated, stored, optimized, and consumed across residential, commercial, industrial, and utility-scale applications. It operates at the intersection of renewable energy infrastructure, energy storage, and software-driven optimization, combining battery systems, solar integration, and proprietary Artificial Intelligence (AI) technologies into unified intelligent energy platforms. Its solutions are designed to help customers reduce energy costs, improve operational resilience, increase energy independence, and optimize energy performance in increasingly decentralized and volatile energy markets. It generates the majority of its revenue from Spain.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.